Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung Cancer

被引:3
|
作者
Evin, Cecile [1 ]
Lassau, Nathalie [1 ,2 ]
Balleyguier, Corinne [1 ,2 ]
Assi, Tarek [3 ]
Ammari, Samy [1 ,2 ]
机构
[1] Univ Paris Saclay, Dept Imaging, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, CNRS, Biomaps, INSERM,CEA,UMR1281, F-94805 Villejuif, France
[3] Univ Paris Saclay, Dept Oncol, Gustave Roussy, F-94805 Villejuif, France
关键词
PRES; chemotherapy; immunotherapy; status epilepticus; diaschisis; LEUKOENCEPHALOPATHY SYNDROME; CARBOPLATIN; IMMUNOTHERAPY;
D O I
10.3390/diagnostics12061369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological complication that occurs following a sudden blood pressure increase. We report the case of a 64-year-old patient presenting PRES several hours after the administration of a combination of chemotherapy and a checkpoint inhibitor (carboplatin-etoposide-atezolizumab) for small-cell lung cancer. He presented consciousness disorders associated with partial epileptic seizure secondarily generalized. His arterial blood pressure was elevated and brain imaging showed multiple bilateral subcortical parietal, temporal, occipital and cerebellar T2 high signals, predominantly in the posterior region. There were no abnormal T1 signals nor bleeding but a left apparent diffusion coefficient restriction was noted. On arterial spin labelling perfusion sequences, there was an increased perfusion within the left temporo-parieto-occipital, left thalamic and right cerebellar regions. Finally, the neurological symptoms completely regressed after several days of optimal antihypertensive and antiepileptic treatment. The clinical context and radiological features, as well as the progressive resolution of the neurological symptoms, were all in favor of PRES. PRES can occur after the administration of chemotherapy and/or immunotherapy. Prompt diagnosis is crucial through a spectrum of suspicious clinical and radiological characteristics that must be rapidly recognized to quickly anticipate the optimal therapeutic strategy and avoid unnecessary complications.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] SHORT DURATION COMBINATION CHEMOTHERAPY IN THE TREATMENT OF SMALL-CELL LUNG-CANCER
    DORWARD, AJ
    BANHAM, SW
    HUTCHEON, AW
    AHMEDZAI, S
    CUNNINGHAM, D
    GREGOR, A
    SOUKOP, M
    STACK, BHR
    MACKAY, NSD
    KAYE, SB
    THORAX, 1986, 41 (09) : 688 - 691
  • [32] SEQUENTIAL COMBINATION CHEMOTHERAPY WITH OR WITHOUT IRRADIATION IN SMALL-CELL LUNG-CANCER
    SCHUETTE, J
    NIEDERLE, N
    SEEBER, S
    EBERHARDT, W
    HOFELER, H
    ALBERTI, W
    HIRCHE, H
    SCHMIDT, CG
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 190 - 190
  • [33] COMBINATION CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, EPIRUBICIN AND ETOPOSIDE IN SMALL-CELL LUNG-CANCER
    JASSEM, J
    KARNICKAMLODKOWSKA, H
    JASSEM, E
    SLUPEK, A
    ZYCH, J
    WIATR, E
    MALAK, S
    MOSANTKOWIAK, R
    SZYMACZEKMEYER, L
    PILARSKAMACHOWICZ, A
    JERECZEK, B
    LUNG CANCER, 1994, 11 (3-4) : 283 - 291
  • [34] CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER
    RUFFIE, P
    LECHEVALIER, T
    BULLETIN DU CANCER, 1987, 74 (05) : 531 - 540
  • [35] Chemotherapy of non small-cell lung cancer
    Le Guen, Y
    Soria, JC
    Ruffié, P
    BULLETIN DU CANCER, 2003, 90 (03) : 199 - 201
  • [36] Chemotherapy advances in small-cell lung cancer
    Chan, Bryan A.
    Coward, Jermaine I. G.
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S565 - S578
  • [37] CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER
    HANSEN, HH
    KRISTJANSEN, PEG
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (03) : 342 - 349
  • [38] CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER
    GRECO, FA
    JOHNSON, DH
    HAINSWORTH, JD
    WOLFF, SN
    SEMINARS IN ONCOLOGY, 1985, 12 (04) : 31 - 37
  • [39] The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice
    Zouein, Joseph
    Haddad, Fady G.
    Eid, Roland
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2022, 14 (02) : 155 - 167
  • [40] EFFICACY OF SALVAGE CHEMOTHERAPY AFTER IMMUNE CHECKPOINT INHIBITOR IN NON-SMALL CELL LUNG CANCER PATIENTS
    Okamatsu, Yuki
    Inoue, Shigesato
    Utsumi, Takahiro
    Kayukawa, Takafumi
    Uryu, Kazuyasu
    Inoue, Katsuhiro
    Tsubouchi, Kazuya
    Harada, Taishi
    RESPIROLOGY, 2018, 23 : 286 - 286